In mouse models, microglial depletion improved the cognitive impairments following CAR-T cell therapy targeting CD19 or GD2.5 All these findings should be considered in the context of the disease being treated (cancer vs autoimmunity) and the type of CAR-T cell therapy administered (especially target antigens). The gene discussed is CD19; the disease is Cognitive impairment.